Legend Biotech· @LegendBiotech · X·· 5 天前AI 评分30
AI 导读
#IMS2026 上的 CARTITUDE-2 A队列5年数据 我们公布了 CARTITUDE-2 A队列的长期研究结果，该队列纳入的是早在二线即接受治疗的复发或难治性多发性骨髓瘤（RRMM）患者。 了解更多：https://bit.ly/4hM5WuA #LegendBiotech #MultipleMyeloma #CellTherapy #CART
正文
5-year CARTITUDE-2 Cohort A data at #IMS2026
We presented long-term findings from CARTITUDE-2 Cohort A in patients with relapsed or refractory multiple myeloma (RRMM) treated as early as second line.
Learn more: https://bit.ly/4hM5WuA
#LegendBiotech #MultipleMyeloma #CellTherapy #CART
来源：Legend Biotech · x.com